<DOC>
	<DOCNO>NCT00566631</DOCNO>
	<brief_summary>The purpose study evaluate tolerability , safety treatment response flexible dose paliperidone extended-release ( ER ; design slowly release drug body extend period time ) tablets participant acute schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Paliperidone Extended-Release ( ER ) Tablets Participants With Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-arm ( get one dose medicine ) , multi-center ( conducted 1 center ) study evaluate tolerability , safety efficacy flexible daily dos paliperidone ER participant acute schizophrenia . All participant give paliperidone ER daily dose 3 , 6 , 9 , 12 milligram ( mg ) tablets orally depend Investigator 's discretion , base participant 's clinical response tolerability towards paliperidone ER . The duration core phase treatment 6 week participant complete phase , respond well would like continue , eligible enrol extension phase , longer 12 month . Efficacy primarily evaluate treatment response evaluate total Positive Negative Syndrome Scale ( PANSS ) score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Meets Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criteria schizophrenia Must experience acute schizophrenic episode Positive Negative Syndrome Scale ( PANSS ) total score great equal 70 Baseline Must admit hospital treatment acute schizophrenic episode must agree voluntary hospitalization least first 7 day study Female participant must postmenopausal ( least 1 year ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( example , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study female participant childbearing potential must negative urine pregnancy test Screening Participants legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing participate study Pregnant breastfeed female participant First antipsychotic treatment ever Have receive experimental drug use experimental medical device within 30 day plan start treatment clozapine longacting injectable antipsychotic last 3 month Known hypersensitivity paliperidone extendedrelease ( ER ) risperidone Relevant history significant unstable cardiovascular , respiratory , neurologic ( include seizure significant cerebrovascular ) , renal , hepatic , endocrine , immunologic disease , history current symptom tardive dyskinesia neuroleptic malignant syndrome include recent present clinically relevant laboratory abnormality ( deem Investigator ) participant current know history ( past 6 month ) substance dependence accord DSMIV Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended Release ( ER )</keyword>
	<keyword>Invega</keyword>
</DOC>